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Introduction
Phthalate acid esters,  also known as 
 phthalates, are the predominant type of plasti-
cizer used around the world. Low-molecular-
weight phthalates, such as diethyl phthalate 
(DEP), di-n-butyl phthalate (DnBP), 
and diisobutyl phthalate (DiBP), are used in 
personal care products, solvents, adhesives, 
and medications [Kelley et al. 2012; Koniecki 
et al. 2011; U.S. Environmental Protection 
Agency (EPA) 2012]. High-molecular-weight 
phthalates, such as butylbenzyl phthalate 
(BBzP), di(2-ethylhexyl) phthalate (DEHP), 
diisononyl phthalate (DiNP), and diisodecyl 
phthalate (DiDP), are primarily used as plasti-
cizers in polyvinyl chloride (PVC) applica-
tions found in building materials, cables and 
wires, toys, and food packaging (Schecter 
et al. 2013; Stringer et al. 2000; U.S. EPA 
2012) (Table 1).
Phthalates are not chemically bound 
to products and are therefore released into 
the environment where they may enter the 
human body via ingestion, inhalation, and 
dermal absorption (Meeker et al. 2009). 
Urinary metabolites of DEP, DnBP, BBzP, 
and DEHP have been widely detected in the 
U.S. population since 1999–2000, when 
phthalate metabolites were first systemati-
cally quantified in the National Health and 
Nutrition Examination Survey (NHANES) 
[Centers for Disease Control and Prevention 
(CDC) 2013; Silva et al. 2004; Woodruff 
et al. 2011]. Higher concentrations of some 
phthalate metabolites have been documented 
in certain sociodemographic subpopula-
tions, including children (Koch et al. 2004; 
Wittassek et al. 2011), females (Silva et al. 
2004; Trasande et al. 2013), non white 
popula tions (Kobrosly et al. 2012; Trasande 
et al. 2013), and those of lower socioeconomic 
status (Kobrosly et al. 2012).
In animal studies, phthalates exhibit 
marked differences in toxicity depending 
on their chemical structure and timing of 
the exposure (Foster 2005; Gray et al. 2000; 
Howdeshell et al. 2008; National Research 
Council 2008; Parks et al. 2000). In utero 
exposure to certain phthalates, including 
BBzP, DnBP, and DEHP but not others (e.g., 
DEP), during the sexual differentiation period 
of rat development leads to reproductive tract 
malformations in androgen- and insulin-like 3 
(INSL3)–dependent tissues (Barlow and Foster 
2003; McKinnell et al. 2005; Wilson et al. 
2004). Human epidemiologic studies have 
reported associations between exposure to 
DnBP, BBzP, and some other phthalates and 
adverse male reproductive outcomes, including 
reduced sperm quality, increased sperm DNA 
damage, and altered male genital development 
(Hauser et al. 2006, 2007; Meeker et al. 2009; 
Swan et al. 2005). Other studies have reported 
associations between gestational exposures to 
phthalates, including DEP, DnBP, BBzP, and 
DEHP, and outcomes suggesting impaired 
behavioral develop ment (Braun et al. 2013; 
Engel et al. 2009; Swan et al. 2010; Whyatt 
et al. 2012).
Given the scientific community and 
public’s concern over phthalate toxicity, the 
European Union (EU) has banned the use 
of certain phthalates in toys, food-containing 
materials, and cosmetics (EU 2004, 2005, 
2007). The U.S. federal government enacted 
legislation in 2008 that bans the use of DnBP, 
BBzP, and DEHP in any amount > 0.1% in 
child care articles including toys and placed 
an interim restriction on DiNP, DiDP, and 
di-n-octyl phthalate (DnOP) in toys that can 
be put in a child’s mouth [Consumer Product 
Safety Improvement Act (CPSIA) 2008; U.S. 
EPA 2012]. Although phthalate content in 
other products is not subject to legislative 
oversight in the United States, environmental 
and public health organizations have sought 
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Background: Phthalates are ubiquitous environmental contaminants. Because of potential adverse 
effects on human health, butylbenzyl phthalate [BBzP; metabolite, monobenzyl phthalate (MBzP)], 
di-n-butyl phthalate [DnBP; metabolite, mono-n-butyl phthalate (MnBP)], and di(2-ethylhexyl) 
phthalate (DEHP) are being replaced by substitutes including other phthalates; however, little is 
known about consequent trends in population-level exposures.
oBjective: We examined temporal trends in urinary concentrations of phthalate metabolites in the 
general U.S. population and whether trends vary by sociodemographic characteristics.
Methods: We combined data on 11 phthalate metabolites for 11,071 participants from five cycles 
of the National Health and Nutrition Examination Survey (2001–2010). Percent changes and least 
square geometric means (LSGMs) were calculated from multivariate regression models.
results: LSGM concentrations of monoethyl phthalate, MnBP, MBzP, and ∑DEHP metabolites 
decreased between 2001–2002 and 2009–2010 [percent change (95% CI): –42% (–49, –34); –17% 
(–23, –9); –32% (–39, –23) and –37% (–46, –26), respectively]. In contrast, LSGM concentra-
tions of monoisobutyl phthalate, mono(3-carboxypropyl) phthalate (MCPP), monocarboxyoctyl 
phthalate, and monocarboxynonyl phthalate (MCNP) increased over the study period [percent 
change (95% CI): 206% (178, 236); 25% (8, 45); 149% (102, 207); and 15% (1, 30), respectively]. 
Trends varied by subpopulations for certain phthalates. For example, LSGM concentrations of 
∑DEHP metabolites, MCPP, and MCNP were higher in children than adults, but the gap between 
groups narrowed over time (pinteraction < 0.01).
conclusions: Exposure of the U.S. population to phthalates has changed in the last decade. Data 
gaps make it difficult to explain trends, but legislative activity and advocacy campaigns by non-
governmental organizations may play a role in changing trends.
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to reduce phthalate exposure by advocating 
for the removal of phthalates from personal 
care products and educating the public about 
how to find potentially safer alternatives 
(Campaign for Safe Cosmetics 2011).
Data on ingredient composition of con­
sumer products are difficult to obtain because 
reporting is not required by law, but there is 
some evidence that the plasticizer market 
is changing. DEHP, which has historically 
been the most common phthalate plasticizer, 
is increasingly being substituted with DiNP 
and DiDP, and these two phthalates combined 
account for 30–60% of the current plasticizer 
market in the United States and the European 
Union (European Chemicals Agency 2012). 
Changes in reformulation and legislation 
may have important implications for phthal­
ates exposures, and subsequent health risks, 
but until now, data were not available to 
assess temporal trends in phthalate exposures. 
Therefore, our study objective was to assess 
temporal trends in exposure to phthalates by 
analyzing changes in mean urinary concentra­
tions of phthalate metabolites in the U.S. popu­
lation between 2001 and 2010. In addition, 
we sought to assess whether temporal trends in 
urinary concentrations of phthalate metabolites 
differ by age, sex, race/ ethnicity, or household 
income because these attributes have previously 
been correlated with phthalate exposures.
Methods
Study population. We used data from the 
2001–2002, 2003–2004, 2005–2006, 
2007–2008, and 2009–2010 cycles of 
NHANES, a nationally representative survey 
and physical examination of the civilian, non­
institutionalized U.S. population conducted 
by the CDC. There were 13,288 participants 
with urinary measurements of phthalate 
metabolites and creatinine. We excluded 
participants who did not self­identify as 
non­Hispanic white, non­Hispanic black, or 
Mexican American (n = 1,460) and/or were 
missing information on household income 
(n = 902), resulting in a final sample size of 
11,071 study participants.
Phthalate metabolite measurements. 
Phthalate metabolites are measured in approxi­
mately one­third of NHANES participants. 
Spot urine samples were collected in the 
Mobile Examination Center and stored at 
–20°C until shipped to the CDC’s National 
Center for Environmental Health (Atlanta, 
GA) for analysis. Concentrations of phthalate 
metabolites were quantified using solid phase 
extraction–high performance liquid chroma­
tography–isotope dilution–tandem mass spec­
trometry (CDC 2013). Laboratory files were 
downloaded from the NHANES website in 
October 2012 and included the needed correc­
tions for impurities in some of the previously 
used analytical standards (Langlois et al. 2012).
Fifteen phthalate metabolites have been 
measured in NHANES, but not all metabo­
lites were measured in all cycles. The limit of 
detection (LOD) for a given metabolite often 
varied by cycle. To facilitate analysis across 
cycles, we assumed the maximal LOD for each 
metabo lite in our analysis, and substituted 
values below the LOD with LOD divided by 
the square root of 2 because this method is 
used by the CDC (2013) and it produces rea­
sonably nonbiased means and SDs (Hornung 
and Reed 1990). This report includes the 
11 metabolites detected in more than 50% 
of the population in each cycle (LODs and 
detection frequencies are available in the 
Supplemental Material, Tables S1 and S2).
We calculated a summary metric for 
DEHP metabolites (∑DEHP metabolites) 
equal to the molar sum of mono(2­ethylhexyl) 
phthalate (MEHP), mono(2­ethyl­5­hydroxy­
hexyl) phthalate (MEHHP), and mono(2­
ethyl­5­oxohexyl) phthalate (MEOHP). [We 
omitted mono(2­ethyl­5­carboxypentyl) 
phthalate (MECPP) because it was not mea­
sured in 2001–2002.] We divided the con­
centrations of each metabolite by its molecular 
weight (MW) to obtain the molar equivalent 
(micromoles per liter) and then summed the 
concentrations in micromoles per liter to 
get total micromoles per liter of metabolites. 
To facilitate comparison with other analytes 
(Frederiksen et al. 2012; Wolff et al. 2010), 
we multiplied total micromoles per liter of 
metabolites by the average MW of the DEHP 
metabolites (MW = 288 μg/μmol) resulting in 
∑DEHP metabolites concentrations expressed 
in nanograms per liter.
Statistical analysis. Analyses were con­
ducted in SUDAAN, version 10.0 (Research 
Triangle Institute, Cary, NC). Because we 
combined five survey cycles, we calculated 
new sample weights for each participant 
according to the NHANES analytical guide­
lines (National Center for Health Statistics 
2006) equal to one­fifth of the 2­year sample 
weights provided in the NHANES laboratory 
files. The degrees of freedom for our study 
sample equaled 77 and was calculated by sub­
tracting the number of clusters in the first 
level of sampling (strata) from the number of 
clusters (PSUs, or primary sampling units) in 
the second level of sampling (National Center 
for Health Statistics 2006). Based on our 
degrees of freedom, we used a critical value of 
±1.99 from the t distribution for the calcula­
tion of all confidence intervals. All analyses 
Table 1. Phthalates and urinary metabolites measured in the NHANES biomonitoring program.
Phthalate Abbrev
Level of restriction 
in the U.S.a MWb Urinary metabolites Abbrev Common sources
Dimethyl phthalate DMP — 194.2 Monomethyl phthalate MMP Insect repellent, plastic bottles, foodc,d
Diethyl phthalate DEP — 222.2 Monoethyl phthalate MEP Fragrance, cosmetics, medicationse,f,g
Di-n-butyl phthalate DnBP ++ 278.4 Mono-n-butyl phthalate MnBP Cosmetics, medications, food packaging, food, 
PVC applicationse,g,h,i,j,k
Diisobutyl phthalate DiBP — 278.3 Monoisobutyl phthalate MiBP Cosmetics, food, food packaginge,f,h,i
Butylbenzyl phthalate BBzP ++ 312.4 Monobenzyl phthalate 
Monobutyl phthalate (minor)
MBzP PVC flooring, food, food packagingh,l
Dicyclohexyl phthalate DCHP — 330.4 Monocyclohexyl phthalate MCHP Food, food packagingh




Di-n-octyl phthalate DnOP + 390.6 Mono(3-carboxypropyl) phthalate MCPPn PVC applications, food, food packagingh,i,j
Monooctyl phthalate MOP
Diisononyl phthalate DiNP + 418.6 Monoisononyl phthalate MiNP PVC applications, toys, flooring, wall coveringj,m,o
Monocarboxyoctyl phthalate MCOP
Diisodecyl phthalate DiDP + 446.4 Monocarboxynonyl phthalate MCNP PVC applications, toys, wire and cables, flooringj,m,o
Abbreviations: —, no use restrictions; +, moderate use restrictions; ++, most use restrictions; abbrev, abbreviation. 
aIndicates degree of risk management activities by federal and state governments in the United States (U.S. EPA 2012). bWe classified DMP, DEP, DnBP, and DiBP as low-molecular-
weight phthalates, and BBzP, DCHP, DEHP, DnOP, DiNP, and DiDP high-molecular-weight phthalates. cKarunamoorthi and Sabesan (2010). dAl-Saleh et al. (2011). eKoniecki et al. (2011). 
fDodson et al. (2012). gKelley et al. (2012). hFierens et al. (2012). iSchecter et al. (2013). jKawakami et al. (2011). kCirillo et al. (2013). lKavlock et al. (2002). mStringer et al. (2000). MCPP is 
also a non specific metabolite of several high-molecular- weight phthalates. oEuropean Chemicals Agency (2012).
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were adjusted for the nonrandom sampling 
design and the sample population weights.
We used multivariable regression models 
to assess the relationship between each phthal-
ate metabolite concentration and time. For 
this analysis, we modeled NHANES sam-
pling cycles using four indicator terms, with 
partici pants sampled in 2001–2002 as the 
reference group. Next, we constructed our 
“core” multivariable regression models where 
the outcome was phthalate metabolite concen-
trations and the independent variables were 
NHANES sampling cycle and urinary creati-
nine concentrations (to account for urinary 
dilution) (Barr et al. 2005). We natural log–
transformed phthalate metabolite and creati-
nine data before regression analysis to account 
for their non-normal distributions. We exam-
ined residual diagnostics after transformation 
to assess these assumptions and tried various 
transformations of the data to assess the sensi-
tivity of the conclusions to the assumptions of 
normality and equal variances.
From these regression models, we esti-
mated a) percent changes in phthalate 
metabolite concentrations by NHANES 
cycle as [exp(β) – 1] × 100% with 95% CIs 
estimated as [exp(β ± 1.99 × SE) – 1] where 
β and SE are the estimated regression coef-
ficient and standard error, respectively; and 
b) least squares geometric means (LSGMs) 
of phthalate metabolites concentrations 
by NHANES cycle as exp(least squares 
means) with 95% CIs as exp(least squares 
mean ± 1.99 × SE) where the least squares 
means is the cycle-specific mean of phthalate 
metabolite concentrations after adjusting for 
covariates. Next, we examined whether asso-
ciations between NHANES sampling cycle 
and phthalate metabolites concentrations var-
ied by age, sex, race/ ethnicity, or household 
income. We first added the four demographic 
covariates to the “core” regression model 
described above. We then modeled multipli-
cative interactions between NHANES cycle 
and each demographic variable one at a time 
by adding product terms to the model for 
the interaction being evaluated, in addition 
to lower-order terms and covariates. LSGMs 
for subgroups presented in the main text 
were calculated from the multivariable mod-
els with the multiplicative interaction terms. 
Demographic variables were categorized as 
follows: age [children (6–11 years; n = 1,568), 
adolescents (12–19 years; n = 2,524), and 
adults (≥ 20 years; n = 6,979)]; sex [male 
(n = 5,524) and female (n = 5,547)]; race/ 
ethnicity [non-Hispanic white (n = 5,305), 
non-Hispanic black (n = 2,951), and Mexican 
American (n = 2,815)]; and poverty–income 
ratio (PIR; the ratio of household income 
to poverty threshold adjusted to family size 
and inflation) [< 1 (i.e., beneath the poverty 
threshold; n = 2,604), 1–3 (n = 4,639), and 
> 3 (n = 3,828)]. This is a descriptive analy-
sis, thus results for individual phthalates are 
not corrected for multiple comparisons. A 
(two-sided) p-value < 0.05 was considered 
 statistically significant.
Results
Concentrations of monobenzyl phthalate 
(MBzP), mono-n-butyl phthalate (MnBP), 
and monoethyl phthalate (MEP), metabolites 
of BBzP, DnBP, and DEP, respectively, were 
detected in at least 98% of participants in each 
cycle. The detection frequency of mono iso-
butyl phthalate (MiBP), a metabolite of DiBP, 
increased monotonically from 72% in 2001–
2002 to 96% in 2009–2010. Concentrations 
of MEOHP, mono(3-carboxypropyl) phthal-
ate (MCPP), monocarboxyoctyl phthal-
ate (MCOP), monocarboxynonyl phthalate 
(MCNP), oxidative metabolites of DEHP, 
DnOP, DiNP, and DiDP, respectively, 
were detected in more than 89% of partici-
pants. (see Supplemental Material, Table S2; 
 comparisons made using maximal LODs).
Concentrations of MEP, MnBP, MBzP, 
and the DEHP metabolites were significantly 
lower in 2009–2010 than in 2001–2002 
(Figure 1; see also Supplemental Material, 
Table S3). LSGM concentrations of MEP 
declined monotonically between 2005 
and 2010; compared with 2001–2002, 
LSGM concentrations were 20% (95% CI: 
–30, –9%) and 42% (95% CI: –49, –34%) 
lower in 2007–2008 and 2009–2010, 
respectively. LSGM concentrations of 
MBzP also steadily declined over time with 
the largest percent change [–32% (95% CI: 
–39, –23%)] observed between 2001–2002 
and 2009–2010. There were no significant 
differences in LSGM concentrations of MnBP 
between 2001 and 2008, but 2009–2010 
LSGMs were 17% lower (95% CI: –23, –9%) 
than those in 2001–2002. The temporal trend 
for ∑DEHP metabolites was non monotonic; 
LSGM concentrations of ∑DEHP metabolites 
increased from 39.3 ng/mL (95% CI: 36.3, 
42.5) in 2001–2002 to 45.4 ng/mL (95% CI: 
41.4, 49.7) in 2005–2006 and then decreased 
to 24.8 ng/mL (95% CI: 21.5, 28.5) 
in 2009–2010.
Concentrations of MiBP, MCPP, MCOP, 
and MCNP were highest in 2009–2010 
compared with earlier study cycles (Figure 2; 
see also Supplemental Material, Table S3). 
LSGM concentrations of MiBP monotonically 
increased over time and were 206% higher 
(95% CI: 178, 236%) in 2009–2010 com-
pared with 2001–2002. LSGM concentra-
tions of MCOP also monotonically increased 
over time and were 149% higher (95% CI: 
Figure 1. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. popu-
lation for (A) MEP (n = 11,071; parent phthalate = DEP) (p < 0.0001); (B) MnBP (n = 11,071; parent phthalate, 
DnBP; p < 0.0001); (C) MBzP (n = 11,071; parent phthalate, BBzP; p < 0.0001); and (D) ∑DEHP metabolites 
(n = 11,071; parent phthalate, DEHP; p < 0.0001). Models are adjusted for urinary creatinine. Data points rep-
resent LSGM and error bars represent 95% CIs. Corresponding numeric data are provided in Supplemental 
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102, 207%) in 2009–2010 compared with 
2005–2006 (earliest cycle). For MCNP, 
LSGM concentrations were 15% higher 
(95% CI: 1, 30%) in 2009–2010 compared 
with 2005–2006 (earliest cycle) although 
LSGM concentrations in 2005–2006 and 
2007–2008 were statistically similar. The trend 
in LSGM concentrations of MCPP was non-
monotonic with the lowest LSGM occurring 
in 2005–2006.
Temporal trends varied by age for MEP, 
∑DEHP metabolites, MCPP, and MCNP 
(Figure 3; see also Supplemental Material, 
Table S4). For MEP and ∑DEHP metabo-
lites, all three age groups had significantly 
lower concentrations in 2009–2010 compared 
with 2001–2002 but children had some nota-
ble differences compared with that of adoles-
cents and adults (pinteraction = 0.04 and 0.002 
for MEP and ∑DEHP metabolites, respec-
tively). Children had the lowest LSGM con-
centrations of MEP in all cycles with relatively 
stable exposures between 2001 and 2008; 
whereas LSGM concentrations of MEP in 
both adolescents and adults steadily declined 
after 2005–2006. For ∑DEHP metabolites, 
children had higher LSGM concentrations 
than adolescents and adults in all cycles but 
the differences between age groups narrowed 
over time. In addition, the temporal trend for 
∑DEHP metabolites in adults and adolescents 
was non monotonic with highest LSGM con-
centrations in 2005–2006. For MCPP, the 
trend was non-monotonic for all three age 
groups, but among adults only, there was a 
statistically significant increase in LSGM con-
centrations between 2001–2002 and 2009–
2010 (pinteraction = 0.0004). Similarly, LSGM 
concentrations of MCNP in 2009–2010 
were higher than those in 2005–2006 (ear-
liest cycle); whereas in children and adoles-
cents, these metabolite concentrations were 
statistically  similar over the study period 
(pinteraction = 0.009).
For MnBP and ∑DEHP metabolites, 
both sexes had significantly lower LSGMs in 
2009–2010 compared with 2001–2002, but 
the percent decrease was greater in females 
than males (pinteraction = 0.03 and 0.0001, 
respectively) (Figure 4; see also Supplemental 
Material, Table S5). Trends also varied by 
race/ ethnicity and PIR for ∑DEHP metabo-
lites (pinteraction = 0.006 and 0.01, respectively) 
and by PIR for MCPP (pinteraction < 0.0001) 
(Figure 5). For example, the association 
between PIR and MCPP concentrations var-
ied by cycle. In 2001–2002, participants with 
the lowest income (PIR < 1) had the highest 
LSGM concentrations of MCPP. However, 
in 2009–2010, income was inversely associ-
ated with MCPP concentrations and those 
with the highest income (PIR > 3) had a sig-
nificantly higher LSGM of MCPP than those 
with the lowest income.
Figure 2. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. 
population for (A) MiBP (n = 11,071; parent phthalate, DiBP; p < 0.0001); (B) MCPP (n = 11,071; parent 
phthalates, DnOP and a nonspecific metabolite of high-molecular-weight phthalates; p < 0.0001); (C) MCOP 
(n = 6,375; parent phthalate, DiNP; p < 0.0001); and (D) MCNP (n = 6,375; parent phthalate, DiDP; p = 0.004). 
Models are adjusted for urinary creatinine. Data points represent LSGM and error bars represent 95% 
CIs. Corresponding numeric data are provided in Supplemental Material, Table S3. p-Value for the overall 
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Figure 3. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. 
population by age for (A) MEP (pinteraction = 0.04), (B) ∑DEHP metabolites (pinteraction = 0.002), (C) MCPP 
(pinteraction = 0.0004), and (D) MCNP (pinteraction = 0.009). Estimates are from linear regression models 
of interactions between NHANES sampling cycles and age adjusted for urinary creatinine, sex, race/ 
ethnicity, and PIR. Data points represent LSGM and error bars represent 95% CIs. Corresponding numeric 
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Discussion
We observed pronounced changes in uri-
nary concentrations of phthalate metabolites 
among the U.S. population between 2001 
and 2010; urinary metabolite concentrations 
of DEP, DnBP, BBzP, and DEHP declined 
approximately 20–50%, whereas urinary 
metabolite concentrations of DiBP and DiNP 
increased by > 100%. To our knowledge, 
this is the first examination to date of tem-
poral trends in phthalates exposures among a 
large, nationally representative sample of the 
U.S. population. Our findings are consistent 
with those from a German biomonitoring 
study that examined temporal trends over 
two decades in a convenience sample of pre-
dominately university students (age range, 
20–29 years) (Wittassek et al. 2007).
Significant data gaps make it difficult 
to identify the underlying reasons for the 
observed trends in phthalate exposure with 
certainty. Although biomonitoring studies are 
useful for documenting population exposures 
to environmental chemicals, they are limited 
in their ability to identify the contribution of 
specific sources to personal exposure. Another 
data source that could provide insight on 
our findings is chemical production data 
available from the U.S. EPA (Chemical 
Data Reporting; http://epa.gov/cdr/). The 
data available for our study period suggest 
relatively stable trends in production for 
most phthalates (see Supplemental Material, 
Table S6). However, it is difficult to assess 
temporal trends in U.S. phthalate production 
with this data because chemical production 
by year is reported as a range (e.g., 100–
500 million pounds/year) and not available 
on an annual basis but instead in 4- to 6-year 
intervals. In Germany, where more precise 
data is readily available, researchers report 
that a decline in production was accompanied 
by a decline in exposure to DnBP and DEHP 
(Wittassek et al. 2011).
As expected, we observed declines in 
metabolites of those phthalates that have 
been the focus of legislative activities, includ-
ing bans on DnBP, BBzP, and DEHP in 
children’s products. However, legislative 
activity does not entirely explain the observed 
trends. For example, among the phthalates 
in the present study, we found the largest 
reductions in metabolite concentrations of 
DEP, a phthalate used in fragrances that is 
neither regulated in the United States or the 
European Union. In addition, metabolites of 
DnBP, BBzP, and DEHP were still detected 
in nearly all participants and the decline in 
DnBP metabolite concentrations was modest.
The success of advocacy efforts by public 
health and environmental organizations such 
as the Campaign for Safe Cosmetics (2014) 
may partly explain some of our findings. This 
campaign began in 2002 with a landmark 
report that documented widespread detection 
of DEP, DnBP, BBzP, and DEHP in the 
majority of beauty products tested (Houlihan 
et al. 2002). Over the last decade, it has used 
a multi prong strategy to reduce phthalate 
exposures from cosmetics by increasing con-
sumer awareness of phthalate toxicity, cre-
ating a market for phthalate-free products, 
and pressuring the cosmetics industry to 
disclose chemical ingredients in their prod-
ucts (Campaign for Safe Cosmetics 2011). 
Although there are few data available on the 
extent of product reformulation in the United 
States, there is some evidence to suggest that 
the campaign’s activities have been influen-
tial in changing industry practices. For exam-
ple, there has been an increased consumer 
demand for alternative products making it 
the fastest growing sector of the cosmetics 
market (Campaign for Safe Cosmetics 2011). 
Since 2004, more than 1,000 companies have 
pledged to remove chemicals of concern from 
personal care products and increase trans-
parency of chemical ingredients in their prod-
ucts (Campaign for Safe Cosmetics 2011). 
In 2008, the coalition tested a subset of 
products originally examined in 2002 and 
Figure 4. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. popu-
lation by sex for (A) MnBP (pinteraction = 0.03) and (B) ∑DEHP metabolites (pinteraction = 0.0001). Estimates are 
from linear regression models of interactions between NHANES sampling cycles and sex, adjusted for 
urinary creatinine, age (continuous), race/ ethnicity, and PIR. Data points represent LSGM and error bars 
represent 95% CIs. Corresponding numeric data are provided in Supplemental Material, Table S5.
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Figure 5. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. population by race/ ethnicity for ∑DEHP metabolites 
(A; pinteraction = 0.006) and by PIR for ∑DEHP metabolites (B; pinteraction = 0.01) and MCPP (C; pinteraction < 0.0001). Estimates in (A) are from linear regression models of 
interactions between NHANES sampling cycles and race/ ethnicity adjusted for urinary creatinine, age (continuous), sex, and PIR. Estimates in (B) and (C) are 
from linear regression models of interactions between NHANES sampling cycles and PIR adjusted for urinary creatinine, age (continuous), sex, and race/ 
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found less frequent detection and lower con-
centrations of phthalates in most products 
(Campaign for Safe Cosmetics 2008). Our 
data suggest that reductions in DEP expo-
sures have been the most pronounced, pos-
sibly because of changes in the formulation 
or use of personal care products, which are an 
important source of exposure to DEP (Duty 
et al. 2005; Just et al. 2010; Koch et al. 2013; 
Wormuth et al. 2006). Consistent with this 
hypothesis, metabolites of DnBP and DEHP 
declined less than DEP in NHANES over 
the study period. Diet is considered to be a 
principle route of DEHP exposure (Fromme 
et al. 2007; Koch et al. 2013; Wormuth et al. 
2006), and DnBP exposures are not read-
ily explained by either personal care product 
use or food-related sources (Duty et al. 2005; 
Fromme et al. 2007; Just et al. 2010; Koch 
et al. 2013). Future studies should examine 
how concentrations of individual phthalates 
in common exposure sources (such as build-
ing materials, cosmetics, and food) are chang-
ing over time. Moreover, future intervention 
efforts should consider aggregate sources of 
exposure if the goal is to reduce overall risk.
The rise in metabolite concentrations of 
DiBP and some high-molecular-weight phthal-
ates suggest that manufacturers may be using 
them as substitutes for other phthalates even 
though the U.S. EPA has expressed concern 
about their use (U.S. EPA 2012), and there 
is an interim restriction on DnOP, DiNP, 
and DiDP in certain children’s toys (CPSIA 
2008). DiBP is structurally similar to DnBP 
and may be a substitute for DnBP (Wittassek 
et al. 2007). DiNP and DiDP are replacing 
DEHP as a plasticizer in the global market 
(European Chemicals Agency 2012), includ-
ing in the green or “safer alternatives” market 
(Dodson et al. 2012). For example, Dodson 
et al. (2012) measured chemical ingredients in 
conventional and alternative consumer prod-
ucts purchased in 2007 and detected DiNP 
in alternative products only. Similarly, they 
detected DiBP but not DnBP in nail polish 
samples. Toxicological studies suggest that 
DiBP and DiNP may disrupt androgen signal-
ing and act cumulatively with other phthal-
ates to affect male reproductive end points 
(National Research Council 2008). Although 
epidemiologic evidence of these replacement 
phthalates is limited, a recent cross-sectional 
study of 623 Norwegian children (Bertelsen 
et al. 2013) reported associations between cur-
rent asthma and urinary metabolites of DiNP 
and DiDP, but not with any of the other 
phthalate metabolites. Given the likely increase 
in human exposure to replacement phthalates, 
further study on their adverse health effects in 
epidemiologic studies is warranted.
Our findings also suggest that temporal 
trends in phthalates exposure are not uniform 
across the population and that subpopulations 
with the highest initial phthalates exposures 
often experienced the greatest decline over 
the study period. For example, we observed 
a more rapid decline in DEP metabolite 
concentrations in adults and adolescents 
compared with children, possibly reflecting 
differences in personal care product use. We 
also found a greater decline in concentrations 
of DnBP and DEHP metabolites among 
females than males, potentially reflecting dif-
ferences in exposure sources or behavior. For 
example, a Swiss study of 1,215 participants 
found that women have a higher risk percep-
tion of chemicals and a stronger preference for 
natural food than men (Dickson-Spillmann 
et al. 2011). For high-molecular-weight 
phthalates such as DEHP and DiDP, metabo-
lite concentrations were higher in children 
than adults, but the gap between groups nar-
rowed over time. These phthalates are com-
monly used in PVC applications including 
toys, and the larger reductions among children 
may reflect the legislative emphasis on limiting 
phthalates in children’s toys.
There are several key strengths to our 
study. NHANES provides an unparalleled 
opportunity to document changes in envi-
ronmental chemicals exposures because 
each survey captures a large, nationally 
representative sample of the general U.S. 
population that is diverse with respect to 
geography, age, race/ ethnicity, and income. 
The large and diverse sample allows for 
statistically reliable  assessment of trends in 
 demographic subgroups.
Our main study limitation is the cross-
sectional design of NHANES that inhibits 
examination of longitudinal changes in 
phthalates metabolite concentrations in the 
same participants. Also, NHANES does not 
measure phthalate metabolites in children 
< 6 years of age. Our findings may not be gen-
eralizable to young children, who may experi-
ence different exposures to some phthalates 
than older children as a result of their higher 
food consumption related to body weight, 
higher dust ingestion from their playing hab-
its, and distinct mouthing behavior (Becker 
et al. 2009; Wittassek et al. 2011); children 
also possess different behaviors and physiology 
than adults (U.S. EPA 2008). Additional bio-
monitoring studies in young children may be 
warranted because of their potentially higher 
susceptibility to the adverse effects of environ-
mental stressors and because young children 
are likely to be most impacted by regulations 
limiting phthalate content in toys. There may 
be false positives due to the large number of 
models evaluated. However, all of our main 
findings (presented in Figures 1 and 2) and 
half of the interaction models would pass 
Bonferroni correction for multiple testing. 
Last, although the CDC conducted all phthal-
ate metabolite measurements, modifications 
were made to the analytical methods between 
cycles that may affect the frequency of detec-
tion of the measured metabolites. To account 
for some of these differences, we applied the 
same LOD to each cycle.
Conclusions
Our analysis of biomonitoring data from 
a nationally representative sample suggests 
that U.S. population exposure to phthalates 
has changed in the last decade. Although 
exposures to DnBP, BBzP, and DEHP have 
declined, exposures to replacement phthal-
ates such as DiNP and DiBP have increased. 
The observed temporal trends are difficult 
to explain because of significant data gaps, 
but may at least partly reflect the effects of 
legislative activity and the advocacy efforts 
of non governmental organizations on con-
sumer behavior and the use of phthalates in 
 consumer products.
RefeRences
Al-Saleh I, Shinwari N, Alsabbaheen A. 2011. Phthalates resi-
dues in plastic bottled waters. J Toxicol Sci 36:469–478.
Barlow NJ, Foster PM. 2003. Pathogenesis of male reproductive 
tract lesions from gestation through adulthood following 
in utero exposure to di (n-butyl) phthalate. Toxicol Pathol 
31:397–410.
Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, 
Pirkle JL. 2005. Urinary creatinine concentrations in the 
U.S. population: implications for urinary biologic monitoring 
measurements. Environ Health Perspect 113:192–200; 
doi:10.1289/ehp.7337.
Becker K, Güen T, Seiwert M, Conrad A, Pick-Fuß H, Müller J, 
et al. 2009. GerES IV: phthalate metabolites and bisphenol A 
in urine of German children. Int J Hyg Envir Heal 212:685–692.
Bertelsen RJ, Carlsen KCL, Calafat AM, Hoppin JA, Håland G, 
Mowinckel P, et al. 2013. Urinary biomarkers for phthalates 
associated with asthma in Norwegian children. Environ 
Health Perspect 121:251–256.
Braun JM, Sathyanarayana S, Hauser R. 2013. Phthalate expo-
sure and children’s health. Curr Opin Pediatr 25:247–254.
Campaign for Safe Cosmetics. 2008. A Little Prettier. Available: 
http://www.safecosmetics.org/downloads/A-Little-
Prettier_Dec08.pdf [accessed 23 January 2014].
Campaign for Safe Cosmetics. 2011. Market Shift: The Story 
of the Compact for Safe Cosmetics and the Growth in 
Demand for Safe Cosmetics. Available: http://www.
safecosmetics.org/downloads/MarketShift_CSC_Dec2011.
pdf [accessed 23 January 2014].
Campaign for Safe Cosmetics. 2014. The Campaign for 
Safe Cosmetics Homepage. Available: http://www.
safecosmetics.org [accessed 22 January 2014].
CDC (Centers for Disease Control and Prevention). 2013. Fourth 
National Report on Human Exposure to Environmental 
Chemicals: Updated Tables. Atlanta, GA. Available: http://
www.cdc.gov/exposurereport/ [accessed 23 January 2014].
Cirillo T, Fasano E, Esposito F, Del Prete E, Cocchieri RA. 2013. 
Study on the influence of temperature, storage time and 
packaging type on di-n-butylphthalate and di(2-ethylhexyl)
phthalate release into packed meals. Food Addit Contam 
Part A Chem Anal Control Expo Risk Assess 30:403–411.
CPSIA (Consumer Product Safety Improvement Act). 2008. 
Public Law 110–314.
Dickson-Spillmann M, Siegrist M, Keller C. 2011. Attitudes 
toward chemicals are associated with preference for natu-
ral food. Food Qual Prefer 22:149–156.
Dodson RE, Nishioka M, Standley LJ, Perovich LJ, Brody JG, 
Rudel RA. 2012. Endocrine disruptors and asthma- 
associated chemicals in consumer products. Environ 
Health Perspect 120:935–943; doi:10.1289/ehp.1104052.
Duty SM, Ackerman RM, Calafat AM, Hauser R. 2005. Personal 
care product use predicts urinary concentrations of some 
phthalate monoesters. Environ Health Perspect 113:1530; 
doi:10.1289/ehp.8083.
Temporal trends in phthalates
Environmental Health Perspectives • volume 122 | number 3 | March 2014 241
Engel SM, Zhu C, Berkowitz GS, Calafat AM, Silva MJ, 
Miodovnik A, et al. 2009. Prenatal phthalate exposure and 
performance on the Neonatal Behavioral Assessment Scale 
in a multiethnic birth cohort. Neurotoxicology 30:522–528.
EU (European Union). 2004. Commission Directive 2004/93/EC of 21 
September 2004 Amending Council Directive 76/768/EEC for 
the Purpose of Adapting Its Annexes II and III to Technical 
Progress. Off J Eur Union L 300:25.9.2004, 13–41. Available: 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2
004:300:0013:0041:EN:PDF [accessed 23 January 2014].
EU (European Union). 2005. Directive 2005/84/EC of the European 
Parliament and of the Council 14 December 2005 Amending 
for the 22nd time Council Directive 76/769/EEC on the 
Approximation of the Laws, Regulations and Administrative 
Provisions of the Member States Relating to Restrictions on 
the Marketing and Use of Certain Dangerous Substances 
and Preparations (Phthalates in Toys and Childcare 
Articles). Off J Eur Union L 344:27.12.2005, 40–43. Available: 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ
:L:2005:344:0040:0043:EN:PDF [accessed 23 January 2014].
EU (European Union). 2007. Commission Directive 2007/19/EC 
of 30 March 2007 Amending Directive 2002/72/EC Relating 
to Plastic Materials and Articles Intended to Come into 
Contact with Food and Council Directive 85/572/EEC 
Laying Down the List of Simulants to Be Used for Testing 
Migration of Constituents of Plastic Materials and Articles 
Intended to Come into Contact with Foodstuffs. Off J Eur 
Union L 91:31.3.2007, 17–36. Available: http://eur-lex.europa.
eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:091:0017:0036:E
N:PDF [accessed 23 January 2014].
European Chemicals Agency. 2012. Evaluation of New Scientific 
Evidence Concerning DINP and DIDP in Relation to Entry 
52 of Annex XVII to Regulation (EC) No 1907/2006 (REACH).
Fierens T, Servaes K, Van Holderbeke M, Geerts L, De Henauw S, 
Sioen I, et al. 2012. Analysis of phthalates in food products 
and packaging materials sold on the Belgian market. Food 
Chem Toxicol 50:2575–2583.
Foster P. 2005. Disruption of reproductive development in male 
rat offspring following in utero exposure to phthalate 
esters. Int J Androl 29:140–147.
Frederiksen H, Sorensen K, Mouritsen A, Aksglaede L, Hagen C, 
Petersen J, et al. 2012. High urinary phthalate concentra-
tion associated with delayed pubarche in girls. Int J Androl 
35:216–226.
Fromme H, Gruber L, Schlummer M, Wolz G, Böhmer S, Angerer J, 
et al. 2007. Intake of phthalates and di (2-ethyl hexyl) adipate: 
results of the Integrated Exposure Assessment Survey based 
on duplicate diet samples and biomonitoring data. Environ Int 
33:1012–1020.
Gray LE Jr, Ostby J, Furr J, Price M, Veeramachaneni DN, 
Parks L. 2000. Perinatal exposure to the phthalates DEHP, 
BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual 
differentiation of the male rat. Toxicol Sci 58:350–365.
Hauser R, Meeker JD, Duty S, Silva MJ, Calafat AM. 2006. 
Altered semen quality in relation to urinary concentra-
tions of phthalate monoester and oxidative metabolites. 
Epidemiology 17:682–691.
Hauser R, Meeker J, Singh N, Silva M, Ryan L, Duty S, et al. 
2007. DNA damage in human sperm is related to urinary 
levels of phthalate monoester and oxidative metabolites. 
Hum Reprod 22:688–695.
Hornung RW, Reed LD. 1990. Estimation of average concentration 
in the presence of nondetectable values. Appl Occup Environ 
Hyg 5:46–51.
Houlihan J, Brody C, Schwan B. 2002. Not Too Pretty: 
Phthalates, Beauty Products, and the FDA. Washington, 
D C : E n v i r o n m e n t a l  W o r k i n g  G r o u p .  A v a i l a b l e : 
http://www.safecosmetics.org/downloads/NotTooPretty_
report.pdf [accessed 23 January 2014].
Howdeshell KL, Wilson VS, Furr J, Lambright CR, Rider CV, 
Blystone CR, et al. 2008. A mixture of five phthalate esters 
inhibits fetal testicular testosterone production in the 
Sprague-Dawley rat in a cumulative, dose-additive manner. 
Toxicol Sci 105:153–165.
Just AC, Adibi JJ, Rundle AG, Calafat AM, Camann DE, Hauser R, 
et al. 2010. Urinary and air phthalate concentrations and 
self-reported use of personal care products among minority 
pregnant women in New York City. J Expo Sci Environ 
Epidemiol 20:625–633.
Karunamoorthi K, Sabesan S. 2010. Laboratory evaluation of 
dimethyl phthalate treated wristbands against three pre-
dominant mosquito (Diptera: Culicidae) vectors of disease. 
Eur Rev Med Pharmacol Sci 14:443–448.
Kavlock R, Boekelheide K, Chapin R, Cunningham M, Faustman E, 
Foster P, et al. 2002. NTP Center for the Evaluation of Risks 
to Human Reproduction: phthalates expert panel report on 
the reproductive and developmental toxicity of butyl benzyl 
phthalate. Reprod Toxicol 16:453–487.
Kawakami T, Isama K, Matsuoka A. 2011. Analysis of phthalic 
acid diesters, monoester, and other plasticizers in polyvinyl 
chloride household products in Japan. J Environ Sci Health 
A Tox Hazard Subst Environ Eng 46:855–864.
Kelley KE, Hernandez-Diaz S, Chaplin EL, Hauser R, Mitchell AA. 
2012. Identification of phthalates in medications and 
dietary supplement formulations in the United States and 
Canada. Environ Health Perspect 120:379–384; doi:10.1289/
ehp.1103998.
Kobrosly RW, Parlett LE, Stahlhut RW, Barrett ES, Swan SH. 
2012. Socioeconomic factors and phthalate metabolite con-
centrations among United States women of reproductive 
age. Environ Res 115:11–17.
Koch HM, Drexler H, Angerer J. 2004. Internal exposure of 
nursery-school children and their parents and teachers to 
di(2-ethylhexyl)phthalate (DEHP). Int J Hyg Environ Health 
207:15–22.
Koch HM, Lorber M, Christensen KLY, Pälmke C, Koslitz S, 
Brüning T. 2013. Identifying sources of phthalate exposure 
with human biomonitoring: Results of a 48 h fasting study 
with urine collection and personal activity patterns. Int J Hyg 
Environ Health 216:672–681.
Koniecki D, Wang R, Moody RP, Zhu J. 2011. Phthalates in cos-
metic and personal care products: concentrations and possi-
ble dermal exposure. Environ Res 111:329–336.
Langlois É, LeBlanc A, Simard Y, Thellen C. 2012. Accuracy 
investigation of phthalate metabolite standards. J Anal 
Toxicol 36:270–279.
McKinnell C, Sharpe RM, Mahood K, Hallmark N, Scott H, Ivell R, 
et al. 2005. Expression of insulin-like factor 3 protein in the 
rat testis during fetal and postnatal development and in 
relation to cryptorchidism induced by in utero exposure to 
di (n-butyl) phthalate. Endocrinology 146:4536–4544.
Meeker JD, Sathyanarayana S, Swan SH. 2009. Phthalates and 
other additives in plastics: human exposure and associa-
ted health outcomes. Philos Trans R Soc Lond B Biol Sci 
364:2097–2113.
National Center for Health Statistics. 2006. Analytical and 
Reporting Guidelines: The National Health and Nutritional 
Examination Survey (NHANES). Hyattsville, MD:National 
Center for Health Statistics.
National Research Council. 2008. Phthalates and Cumulative Risk 
Assessment: The Tasks Ahead. Washington, DC:National 
Academies Press.
Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, 
Barlow NJ, et al. 2000. The plasticizer diethylhexyl phthalate 
induces malformations by decreasing fetal testosterone 
synthesis during sexual differentiation in the male rat. 
Toxicol Sci 58:339–349.
Schecter A, Lorber M, Guo Y, Wu Q, Yun SH, Kannan K, et al. 
2013. Phthalate concentrations and dietary exposure 
from food purchased in New York State. Environ Health 
Perspect 121:473–494; doi:10.1289/ehp.1206367.
Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, 
et al. 2004. Urinary levels of seven phthalate metabolites in 
the U.S. population from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2000. Environ Health 
Perspect 112:331–338; doi:10.1289/ehp.6723.
Stringer R, Labunska I, Santillo D, Johnston P, Siddorn J, 
Stephenson A. 2000. Concentrations of phthalate esters 
and identification of other additives in PVC children’s toys. 
Environ Sci Pollut Res Int 7:27–36.
Swan SH, Liu F, Hines M, Kruse RL, Wang C, Redmon JB, et al. 
2010. Prenatal phthalate exposure and reduced masculine 
play in boys. Int J Androl 33:259–269.
Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, 
et al. 2005. Decrease in anogenital distance among male 
infants with prenatal phthalate exposure. Environ Health 
Perspect 113:1056–1061; doi:10.1289/ehp.8100.
Trasande L, Attina TM, Sathyanarayana S, Spanier AJ, 
Blustein J. 2013. Race/ethnicity-specific associations 
of urinary phthalates with childhood body mass in a 
nationally representative sample. Environ Health Perspect 
121:501–506; doi:10.1289/ehp.1205526.
U.S. EPA (U.S. Environmental Protection Agency). 2008. Child-
Specific Exposure Factors Handbook. Available: http://
cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=199243 
[accessed 23 January 2014].
U.S. EPA (U.S. Environmental Protection Agency). 2012. 




Whyatt RM, Liu X, Rauh VA, Calafat AM, Just AC, Hoepner L, 
et al. 2012. Maternal prenatal urinary phthalate metabolite 
concentrations and child mental, psychomotor, and 
behavioral development at 3 years of age. Environ Health 
Perspect 120:290–295; doi:10.1289/ehp.1103705.
Wilson VS, Lambright C, Furr J, Ostby J, Wood C, Held G, et al. 
2004. Phthalate ester-induced gubernacular lesions are 
associated with reduced insl3 gene expression in the fetal 
rat testis. Toxicol Lett 146:207–215.
Wittassek M, Koch HM, Angerer J, Brüning T. 2011. Assessing 
exposure to phthalates—the human biomonitoring 
approach. Mol Nutr Food Res 55:7–31.
Wittassek M, Wiesmüller GA, Koch HM, Eckard R, Dobler L, 
Müller J, et al. 2007. Internal phthalate exposure over the 
last two decades—a retrospective human biomonitoring 
study. Int J Hyg Environ Health 210:319.
Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, 
et al. 2010. Investigation of relationships between urinary 
biomarkers of phytoestrogens, phthalates, and phenols 
and pubertal stages in girls. Environ Health Perspect 
118:1039–1046; doi:10.1289/ehp.0901690.
Woodruff TJ, Zota AR, Schwartz JM. 2011. Environmental 
chemicals in pregnant women in the United States: 
NHANES 2003–2004. Environ Health Perspect 119:878–885; 
doi:10.1289/ehp.1002727.
Wormuth M, Scheringer M, Vollenweider M, Hungerbühler K. 
2006. What are the sources of exposure to eight fre-
quently used phthalic acid esters in Europeans? Risk Anal 
26:803–824.
